Listed

Relay Therapeutics, Inc.

RLAYNasdaqCIK 1812364HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$350.0k, Q2 FY2026
Operating income−$90.8m, Q2 FY2026
Net income−$83.7m, Q2 FY2026
Relay Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m25.2Revenue, Q3 FY2023, three months to 2023-09-30$25.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure(0.0)Revenue, Q4 FY2023, three months to 2023-12-31−$1.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure10.0Revenue, Q1 FY2024, three months to 2024-03-31$10.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure7.7Revenue, Q1 FY2025, three months to 2025-03-31$7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure0.7Revenue, Q2 FY2025, three months to 2025-06-30$677.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure7.0Revenue, Q4 FY2025, three months to 2025-12-31$7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure3.0Revenue, Q1 FY2026, three months to 2026-03-31$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure0.4Revenue, Q2 FY2026, three months to 2026-06-30$350.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Research and development$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$m(73.6)Operating income, Q3 FY2023, three months to 2023-09-30−$73.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure(92.2)Operating income, Q4 FY2023, three months to 2023-12-31−$92.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(90.4)Operating income, Q1 FY2024, three months to 2024-03-31−$90.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure(101)Operating income, Q2 FY2024, three months to 2024-06-30−$100.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure(96.4)Operating income, Q3 FY2024, three months to 2024-09-30−$96.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure(85.0)Operating income, Q4 FY2024, three months to 2024-12-31−$85.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(84.9)Operating income, Q1 FY2025, three months to 2025-03-31−$84.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(76.8)Operating income, Q2 FY2025, three months to 2025-06-30−$76.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure(80.4)Operating income, Q3 FY2025, three months to 2025-09-30−$80.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure(60.6)Operating income, Q4 FY2025, three months to 2025-12-31−$60.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(78.6)Operating income, Q1 FY2026, three months to 2026-03-31−$78.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(90.8)Operating income, Q2 FY2026, three months to 2026-06-30−$90.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Net income$m(65.7)Net income, Q3 FY2023, three months to 2023-09-30−$65.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure(83.5)Net income, Q4 FY2023, three months to 2023-12-31−$83.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(81.4)Net income, Q1 FY2024, three months to 2024-03-31−$81.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure(92.2)Net income, Q2 FY2024, three months to 2024-06-30−$92.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure(88.1)Net income, Q3 FY2024, three months to 2024-09-30−$88.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure(76.0)Net income, Q4 FY2024, three months to 2024-12-31−$76.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(77.1)Net income, Q1 FY2025, three months to 2025-03-31−$77.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure(70.4)Net income, Q2 FY2025, three months to 2025-06-30−$70.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure(74.1)Net income, Q3 FY2025, three months to 2025-09-30−$74.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure(54.9)Net income, Q4 FY2025, three months to 2025-12-31−$54.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(73.3)Net income, Q1 FY2026, three months to 2026-03-31−$73.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure(83.7)Net income, Q2 FY2026, three months to 2026-06-30−$83.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Diluted EPS$ per share(0.54)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figurenot reported(0.62)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure(0.69)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure(0.63)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figurenot reported(0.46)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(0.41)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure(0.43)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figurenot reported(0.41)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(0.41)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Basic EPS$ per share(0.54)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figurenot reported(0.62)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure(0.69)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure(0.63)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figurenot reported(0.46)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.46 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(0.41)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure(0.43)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figurenot reported(0.41)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(0.41)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure

Balance sheet

Cash and equivalents$121.2m, Q2 FY2026
Shareholders' equity$890.0m, Q2 FY2026
Relay Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m151Cash and equivalents, Q3 FY2023, at 2023-09-30$151.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure144Cash and equivalents, FY2023, at 2023-12-31$143.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-26, accession 0000950170-25-027756.Report this figure153Cash and equivalents, Q1 FY2024, at 2024-03-31$152.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure134Cash and equivalents, Q2 FY2024, at 2024-06-30$134.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure152Cash and equivalents, Q3 FY2024, at 2024-09-30$152.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure124Cash and equivalents, FY2024, at 2024-12-31$124.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076739.Report this figure93.5Cash and equivalents, Q1 FY2025, at 2025-03-31$93.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure114Cash and equivalents, Q2 FY2025, at 2025-06-30$113.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure91.6Cash and equivalents, Q3 FY2025, at 2025-09-30$91.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure84.0Cash and equivalents, FY2025, at 2025-12-31$84.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure205Cash and equivalents, Q1 FY2026, at 2026-03-31$204.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure121Cash and equivalents, Q2 FY2026, at 2026-06-30$121.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Current assets$m832Current assets, Q3 FY2023, at 2023-09-30$831.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-058237.Report this figure770Current assets, FY2023, at 2023-12-31$770.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-26, accession 0000950170-25-027756.Report this figure770Current assets, Q1 FY2024, at 2024-03-31$770.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-02, accession 0000950170-24-052135.Report this figure704Current assets, Q2 FY2024, at 2024-06-30$704.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091837.Report this figure865Current assets, Q3 FY2024, at 2024-09-30$865.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure809Current assets, FY2024, at 2024-12-31$809.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076739.Report this figure740Current assets, Q1 FY2025, at 2025-03-31$739.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure680Current assets, Q2 FY2025, at 2025-06-30$680.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure624Current assets, Q3 FY2025, at 2025-09-30$624.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure578Current assets, FY2025, at 2025-12-31$578.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure658Current assets, Q1 FY2026, at 2026-03-31$658.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure928Current assets, Q2 FY2026, at 2026-06-30$928.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Total assets$m907Total assets, Q3 FY2023, at 2023-09-30$907.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0000950170-23-058237.Report this figure844Total assets, FY2023, at 2023-12-31$844.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-26, accession 0000950170-25-027756.Report this figure841Total assets, Q1 FY2024, at 2024-03-31$841.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-02, accession 0000950170-24-052135.Report this figure773Total assets, Q2 FY2024, at 2024-06-30$772.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0000950170-24-091837.Report this figure930Total assets, Q3 FY2024, at 2024-09-30$930.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure871Total assets, FY2024, at 2024-12-31$871.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-076739.Report this figure799Total assets, Q1 FY2025, at 2025-03-31$799.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure729Total assets, Q2 FY2025, at 2025-06-30$728.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure670Total assets, Q3 FY2025, at 2025-09-30$670.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure621Total assets, FY2025, at 2025-12-31$621.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure700Total assets, Q1 FY2026, at 2026-03-31$699.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure967Total assets, Q2 FY2026, at 2026-06-30$967.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Current liabilities$m50.7Current liabilities, Q3 FY2023, at 2023-09-30$50.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-058237.Report this figure30.3Current liabilities, FY2023, at 2023-12-31$30.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-26, accession 0000950170-25-027756.Report this figure37.1Current liabilities, Q1 FY2024, at 2024-03-31$37.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-02, accession 0000950170-24-052135.Report this figure45.0Current liabilities, Q2 FY2024, at 2024-06-30$45.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091837.Report this figure47.0Current liabilities, Q3 FY2024, at 2024-09-30$47.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure50.7Current liabilities, FY2024, at 2024-12-31$50.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076739.Report this figure37.1Current liabilities, Q1 FY2025, at 2025-03-31$37.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure32.5Current liabilities, Q2 FY2025, at 2025-06-30$32.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure32.6Current liabilities, Q3 FY2025, at 2025-09-30$32.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure25.6Current liabilities, FY2025, at 2025-12-31$25.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure29.8Current liabilities, Q1 FY2026, at 2026-03-31$29.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure50.8Current liabilities, Q2 FY2026, at 2026-06-30$50.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Total liabilities$m129Total liabilities, Q3 FY2023, at 2023-09-30$128.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0000950170-23-058237.Report this figure92.0Total liabilities, FY2023, at 2023-12-31$92.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-26, accession 0000950170-25-027756.Report this figure95.7Total liabilities, Q1 FY2024, at 2024-03-31$95.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-02, accession 0000950170-24-052135.Report this figure90.8Total liabilities, Q2 FY2024, at 2024-06-30$90.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0000950170-24-091837.Report this figure91.3Total liabilities, Q3 FY2024, at 2024-09-30$91.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure93.5Total liabilities, FY2024, at 2024-12-31$93.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-076739.Report this figure78.3Total liabilities, Q1 FY2025, at 2025-03-31$78.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure63.2Total liabilities, Q2 FY2025, at 2025-06-30$63.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0000950170-25-105054.Report this figure62.3Total liabilities, Q3 FY2025, at 2025-09-30$62.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure54.3Total liabilities, FY2025, at 2025-12-31$54.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure57.4Total liabilities, Q1 FY2026, at 2026-03-31$57.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure77.4Total liabilities, Q2 FY2026, at 2026-06-30$77.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure
Shareholders' equity$m778Shareholders' equity, Q3 FY2023, at 2023-09-30$778.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0000950170-24-122332.Report this figure752Shareholders' equity, FY2023, at 2023-12-31$752.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-076739.Report this figure746Shareholders' equity, Q1 FY2024, at 2024-03-31$745.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure682Shareholders' equity, Q2 FY2024, at 2024-06-30$681.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure839Shareholders' equity, Q3 FY2024, at 2024-09-30$838.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure778Shareholders' equity, FY2024, at 2024-12-31$777.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure721Shareholders' equity, Q1 FY2025, at 2025-03-31$721.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure666Shareholders' equity, Q2 FY2025, at 2025-06-30$665.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure608Shareholders' equity, Q3 FY2025, at 2025-09-30$607.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269601.Report this figure567Shareholders' equity, FY2025, at 2025-12-31$567.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure642Shareholders' equity, Q1 FY2026, at 2026-03-31$642.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure890Shareholders' equity, Q2 FY2026, at 2026-06-30$890.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure

Cash flow

Operating cash flow−$54.1m, Q2 FY2026
Capital expenditure$1.0k, Q4 FY2025
Relay Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(75.4)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$75.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0000950170-24-122332. Derived: 9-month figure less the 6-month figure.Report this figure(89.2)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$89.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(50.3)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$50.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure(65.8)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$65.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0000950170-25-105054. Derived: 6-month figure less the 3-month figure.Report this figure(75.1)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$75.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269601. Derived: 9-month figure less the 6-month figure.Report this figure(57.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$57.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(73.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$73.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(55.3)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$55.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338056. Derived: 6-month figure less the 3-month figure.Report this figure(62.1)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$62.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269601. Derived: 9-month figure less the 6-month figure.Report this figure(44.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$44.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure(51.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$51.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure(54.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$54.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338056. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.6Capital expenditure, Q3 FY2023, three months to 2023-09-30$590.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0000950170-24-122332. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2023, three months to 2023-12-31$118.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure1.8Capital expenditure, Q1 FY2024, three months to 2024-03-31$1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-05, accession 0000950170-25-063553.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0000950170-25-105054. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2024, three months to 2024-09-30$227.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269601. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2025, three months to 2025-03-31$384.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001193125-26-206454.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$26.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338056. Derived: 6-month figure less the 3-month figure.Report this figure(0.0)Capital expenditure, Q3 FY2025, three months to 2025-09-30−$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269601. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076739. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)110.91m, Q3 FY2022
Relay Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20212021-09-30Q3 FY20222022-09-30
Diluted shares (weighted)m shares92.7Diluted shares (weighted), Q3 FY2021, three months to 2021-09-3092,692,515 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-03, accession 0000950170-22-021892.Report this figure111Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30110,905,940 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-03, accession 0000950170-22-021892.Report this figure

Shares outstanding: 219.14mShares outstanding, period not labelled, at 2026-07-31219,141,631 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338056.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.